VolitionRx
Henderson
About VolitionRx
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease is present. As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life. Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $103.5M
- Funding stage: IPO
- Last round: Grant (Mar 2026)
- Ticker: nysemkt:VNRX
- Website: volition.com
- Phone: +1 (646)-650-1351
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/volitionrx-88245 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.